Pharmaceuticals, Biotechnology and Life Sciences
Ireland has temporarily halted using AstraZeneca’s Covid-19 vaccine Sunday, which came after a report from Norway of patients developing blood clots post inoculation.
Roche said Thursday that the global phase III randomised, double-blind, multicentre study of Actemra®/RoActemra® (tocilizumab) plus Veklury® (remdesivir), versus placebo plus Veklury, did not meet its primary endpoint.
Shield Therapeutics said Tuesday that Australia’s Therapeutics Goods Administration has registered its lead product Feraccru in the Australian Register of Therapeutic Goods to treat iron deficiency with or without anaemia in adults.
Novartis said Tuesday its Phase III CANOPY-2 trial did not meet primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer whose cancer progressed while on or after previous treatments.
Clinerion and Medexprim will set up a joint offering which allows access to de-identified, enriched, longitudinal data points derived from complex medical data sets, which combine electronic health records and their corresponding clinical images, to improve research and help patients receive better care.
Navamedic ASA said Thursday it grew revenues by 17% in the fourth quarter of 2020 compared to the same quarter last year, as it reported revenues of NOK 55.3 million in the fourth quarter of 2020 with an EBITDA of negative NOK 3.7 (€5.4) million driven by both new product launches and investments in further growth initiatives.
Novartis has received approval from the US Food and Drug Administration (FDA) after expanded indication for Entresto to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure.
Novavax and SK Bioscience, a vaccine business subsidiary of SK Group, today announced an expanded collaboration and license agreement to include for Bioscience a license to make and sell Novavax’ Covid-19 vaccine to the Korean government.
The drugs regulator in South Africa’s, SAHPRA, has approved an implementation study of Johnson & Johnson’s COVID-19 vaccine, it said…
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has entered into an agreement to divest its Chinese research and development (R&D) subsidiary Basilea Pharmaceutica China Ltd. (“BPC”), by selling BPC’s parent company BPh Investitionen Ltd. to the U.S.-based custom manufacturing organization PHT International Inc. (“PHT”).